All In Biotech

Drug Trial Radar · NCT02864004

Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

Apomorphine Pump in Early Stage of Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Mar 3, 2017

Primary completion

Jan 12, 2024

Study completion Jan 10, 2025

Sponsor

Lead sponsor
Rennes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the use of the apomorphine pump in earlier stages of Parkinson' Disease (PD), when motor complications have just developed and before patients are significantly affected in their social and occupational functioning. The investigators hypothesize that apomorphine pump is superior in terms of positive impact on quality of life (QoL) to oral medical therapy alone at a relatively early stage of PD, before the appearance of severe disabling motor complications thus favoring the maintain of patients' social and occupational status with a significant positive economic impact of the health system.

Conditions

  • Parkinson's Disease

Interventions

  • ApomorphineDrug

    Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour

  • Best Medical TreatmentOther

    Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in the Parkinson's Disease Quality of Life Questionnaire (PDQ39) summary index between the baseline assessment and the assessment at 12 months' follow upTime frame: 12 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Amiens University Hospital

    Amiens, France

  • Bayonne Côte Basque Hospital

    Bayonne, France

  • Pellegrin University Hospital

    Bordeaux, France

  • Pierre Wertheimer Hospital

    Bron, France

  • Caen University Hospital

    Caen, France

  • Clermont-Ferrand University Hospital

    Clermont-Ferrand, France

  • Lille University Hospital

    Lille, France

  • APHM, hospital of Timone

    Marseille, France

  • Clinique Beau-Soleil

    Montpellier, France

  • Montpellier University Hospital

    Montpellier, France

  • Nancy University Hospital

    Nancy, France

  • Laennec Hospital

    Nantes, France

  • Pasteur 2 University Hospital

    Nice, France

  • Caremeau University Hospital

    Nîmes, France

  • Pitié-Salpêtriere Hospital

    Paris, France

  • Poitiers University Hospital

    Poitiers, France

  • Rennes University Hospital

    Rennes, France

  • Saint-Etienne University Hospital

    Saint-Etienne, France

  • Hautepierre University Hospital

    Strasbourg, France

  • Purpan University Hospital

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.